Technavio has announced their latest drug pipeline analysis report on acromegaly and gigantism. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of acromegaly and gigantism. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005952/en/
Technavio has published a new report on the drug development pipeline for the treatment of acromegaly and gigantism, including a detailed study of the pipeline molecules (Graphic: Business Wire)
Acromegaly and gigantism: An overview
The overproduction of growth hormones causes excessive growth and changes in appearance. In children, this condition is called gigantism, and in adults, it is called acromegaly. When the pituitary gland is not functioning properly or makes too much growth hormone due to a noncancerous tumor in the gland, the body experiences problems with growth and causes gigantism and acromegaly. Acromegaly and gigantism conditions have almost similar symptoms. The symptoms include thickening of the skin on palm and feet, excess increase in height, enlarged hands and feet, fatigue and muscle weakness, headache, deepening of the voice, oily skin, excess sweating, and high blood sugar.
Gigantism or acromegaly is a rare condition characterized by the excessive secretion of growth hormones and elevated insulin-like growth factor 1 (IGF-I) levels. Generally, in about 95% of the cases, acromegaly is associated with a pituitary microadenoma, while the remaining 5% of cases are from non-pituitary ectopic sources of growth hormone.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Acromegaly and gigantism: Segmentation of pipeline molecules
Technavio's research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the subcutaneous mode, with around 39% of the pipeline molecules administered through this mode.
Between companies and institutions, companies led the drug development space for the treatment of acromegaly and gigantism. Some of the key players include Novartis, Peptron, Chiasma, Ipsen Pharma, and DexTech Medical.
Looking for more information? Request your free sample today
Some of the key topics covered in the report include:
1. Scope of the Report
2. Regulatory Framework
3. Drug Development Landscape
- Drugs under development
4. Drug Development Strategies
- Therapies employed
- Route of administration
- Therapeutic modality
- Mechanism of action
5. Recruitment Strategies
- Geographical coverage
- Recruitment status
- Gender
- Age
6. Key Companies
- Type of players
- Company overview
7. Discontinued and Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005952/en/
Contacts:
Technavio Research
Jesse Maida
Media Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com
